From Small Cap: Who needs to do better research as they reported...

From Small Cap:

Who needs to do better research as they reported the deal with Eddingpharm was only done last week
Standard business model

SUDA’s agreements and negotiations are based on the company’s standard business model of product supply and upfront payment, followed by payments for achieving regulatory and sales milestones.
Further to these payments, SUDA receives a handling fee as well as double digit royalties on sales.
The company’s current 10-year forecast (after approvals) on signed deals is approximately $83 million.
Based on current agreements, SUDA has already received $0.97 million in upfront fees and will potentially receive $2 million in milestone payments.
At mid-morning, shares in SUDA Pharmaceuticals were trading 20% higher at $0.006.